Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and ...

This publication demonstrates the novel way in which ATH434 targets the labile, or reactive, form of iron which can be so damaging to cells when in excess. The iron binding properties of ATH434 ...

At the centre of the dermatology market and within the interleukin inhibitor drug class, Sanofi takes a leading position with its blockbuster drug Dupixent (dupilumab), considered as the gold standard ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise ...

The first biologic to enter the COPD market, Dupixent (dupilumab), has paved the way for competitors, demonstrating significant efficacy in reducing exacerbations. Dupixent’s success has highlighted ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...